AJOVista LLC Takes $26,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

AJOVista LLC purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 678 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds and other institutional investors have also bought and sold shares of INBX. Signaturefd LLC increased its stake in Inhibrx by 4,637.5% in the fourth quarter. Signaturefd LLC now owns 758 shares of the company’s stock valued at $29,000 after purchasing an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Inhibrx by 389.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,471 shares of the company’s stock valued at $208,000 after buying an additional 4,354 shares during the period. Arizona State Retirement System bought a new stake in shares of Inhibrx in the 4th quarter valued at $209,000. Exchange Traded Concepts LLC raised its stake in Inhibrx by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,705 shares of the company’s stock worth $255,000 after buying an additional 1,700 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in Inhibrx during the 3rd quarter worth $232,000. Institutional investors own 82.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Lifesci Capital downgraded Inhibrx from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 23rd. JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research note on Tuesday, January 23rd.

Inhibrx Stock Up 0.4 %

Shares of NASDAQ:INBX opened at $34.30 on Tuesday. Inhibrx, Inc. has a 12 month low of $14.31 and a 12 month high of $39.79. The company’s fifty day simple moving average is $35.02 and its 200 day simple moving average is $31.13. The company has a debt-to-equity ratio of 4.78, a quick ratio of 5.25 and a current ratio of 5.24.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.66). The firm had revenue of $1.63 million during the quarter, compared to analyst estimates of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. As a group, equities research analysts predict that Inhibrx, Inc. will post -4.34 earnings per share for the current fiscal year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.